96PAXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts). (23rd October 2018) - Cardone, C; Blauensteiner, B; Moreno-Viedma, V; Paul, M C; Martini, G; Vitiello, P P; Ciardiello, D; Borrelli, C; Poliero, L; Vitale, P; Zanaletti, N; Famiglietti, V; et al.